Estimation of renal absorbed doses in the treatment of neuroendocrine tumors using 177Lu-DOTA-TATE
10.3760/cma.j.issn.0254-5098.2021.09.011
- VernacularTitle:177Lu-奥曲肽治疗神经内分泌肿瘤肾脏吸收剂量估算
- Author:
Feng WANG
1
;
Yongxiang PAN
;
Lixin DING
;
Hua ZHU
;
Jiangyuan YU
;
Zhi YANG
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科，国家药监局放射性药物研究与评价重点实验室，北京市核医学质量控制和改进中心，恶性肿瘤发病机制及转化研究教育部重点实验室 100036
- Keywords:
177Lu;
DOTA-TATE;
Neuroendocrine tumors;
Absorbed dose;
SPECT
- From:
Chinese Journal of Radiological Medicine and Protection
2021;41(9):700-704
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To estimate the renal absorbed dose in the treatment of neuroendocrine tumors using 177Lu-DOTA-TATE and to assess the radiation safety and guide the treatment. Methods:The dosimetric calculations of patients treated with 177Lu-DOTA-TATE were carried out based on planar images of single photon emission computed tomography (SPECT). The regions of interest (ROIs) of the whole body and kidneys were delineated and converted into activity. Accordingly, the time-activity curves of the ROIs were obtained. The effective half-lives and cumulative activity of ROIs were calculated through the fitting of a single exponential equation of the ROIs. Then the absorbed doses were calculated based on the medical internal radiation dosimetry (MIRD) formalism. Results:A total of 11 patients with neuroendocrine tumors received 18 cycles of treatments with 177Lu-DOTA-TATE. The effective half-lives of 177Lu-DOTA-TATE in the whole body and kidneys were 20.0-99.8 h and 38.2-75.2 h, respectively, with an average of (57.3 ± 21.4) h and (53.1 ± 12.5) h, respectively. The renal absorbed doses of 177Lu-DTA-TATE were 0.25-1.48 mGy/MBq, with an average of (0.90 ± 0.31) mGy/MBq. The minimum and maximum renal absorbed doses in a single treatment cycle were 1.8 Gy and 9.6 Gy, respectively, while the maximum renal absorbed dose in multiple treatment cycles was 21.7 Gy. Conclusions:The renal absorbed doses in the treatment of neuroendocrine tumors using 177Lu-DOTA-TATE were estimated. The result indicate that the renal absorbed doses were lower than the tolerable dose limits. This study is expected to guide the precise treatment of neuroendocrine tumors.
